Markets

Patent Cliff Sends Bristol-Myers’ Q2 Earnings Tumbling 28%; Forecast Lowered on Acquisition Costs (BMY)

Pharmaceuticals giant Bristol-Myers Squibb Co. ( BMY ) on Wednesday posted a sharp downturn in second quarter earnings, hurt by expiring drug patents.

The New York-based company reported second quarter net income of $645 million, or 38 cents per share, compared with $902 million, or 52 cents per share, in the year-ago period. Excluding special items, adjusted profit was 48 cents per share.

Revenue fell 18% from last year to $4.44 billion.

On average, Wall Street analysts expected a matching profit of 48 cents per share, on nearly matching revenue of $4.45 billion.

Looking ahead, BMY said it now expects full-year earnings to range from $1.78 to $1.88 per share, down from $1.90 to $2 previously. The company blamed acquisition costs for the lowered guidance, but left its adjusted outlook unchanged.

Bristol-Myers shares were mostly flat in premarket trading Wednesday.

The Bottom Line

We have been recommending shares of Bristol-Myers ( BMY ) since Aug.25, 2009, when the stock was trading at $22.58. The company has a 3.92% dividend yield, based on last night's closing stock price of $34.73.

Bristol-Myers Squibb Co. ( BMY ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMY

Other Topics

Stocks

Latest Markets Videos